2012 Volume 28 Issue 6 Pages 328-333
Aprindine is one of the useful antiarrhythmic agents because it rarely decreases cardiac function or prolongs the QT interval. However, there are few reports regarding the use of aprindine in childhood, especially in early infancy. We report the efficacy of aprindine in three infants with postoperative supraventricular tachycardia and one infant with ectopic atrial tachycardia (EAT) without congenital heart anomalies. Aprindine was effective for one infant with EAT among four cases. Although a relatively large amount of aprindine (a dose of 2 to 3 mg/kg) was administered, serum aprindine concentrations were less than the therapeutic range in most cases. One patient developed liver dysfunction, which may be due to the adverse effect of aprindine, but no other serious adverse effects were noted in three patients. We concluded that aprindine could be a medication to treat early infants with supraventricular tachycardia including EAT.
